Oct 5, 2019 · 27m · a16z
CRISPR 2.0 and the Future of Gene Therapies
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this a16z presentation, Andy Tran details the evolution of genetic engineering from basic CRISPR tools to modern CRISPR 2.0 platforms, highlighting key commercial momentum, technical bottlenecks, and actionable frameworks for building transformative bio startups.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. How this is scored →
The host as informed peer 0.0 Guest teaching 1.9 Guest disagreement 0.1 The host pushing back 0.0
speaking balance: gold is the host, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 2:45 Dismissal of early gene therapy methods
Tran forcefully rejects primitive gene therapy strategies, characterizing transgene addition as jamming foreign genes at random places without fixing root causes.
Hardest push from the host ▶ 0:00 No host pushback presentBecause this episode is a uninterrupted solo presentation by Andy Tran, the host provides zero verbal pushback throughout.
Biggest teaching moment ▶ 11:06 Deep dive into delivery vector limitationsTran delivers an educational overview breaking down why AAV vectors suffer from immunogenicity and re-dosing limitations.
The host holds their own ▶ 0:00 No host expertise demonstratedThe host does not speak or engage during the transcript, leaving no host expertise or pushback moments to evaluate.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The host as informed peer | Guest teaching | Guest disagreement | The host pushing back | Why |
|---|---|---|---|---|---|---|
| Introductory Brand Motion and Legal Disclosures | 0 | 1 | 0 | 0 | Andy Tran delivers a solo presentation outlining the shift toward genetic medicines and FDA approvals. The host does not speak, resulting in host-side scores of zero. | |
| Market Opportunities and Startup Exits | 0 | 2 | 1 | 0 | Tran walks through the history of gene editing from early transgene addition to CRISPR-Cas9, noting early approaches were clunky and sloppy. The monologue format leaves host engagement at zero. | |
| Expansion of the CRISPR Protein Toolbox | 0 | 2 | 0 | 0 | Tran explains how CRISPR is evolving into a biological search engine platform beyond simple molecular scissors. No host interaction occurs during this segment. | |
| Tailwinds for Building Next-Gen Gene Therapy Startups | 0 | 2 | 0 | 0 | Tran details developer ecosystem expansion and favorable regulatory tailwinds from the FDA for gene therapy startups. Host activity remains entirely absent. | |
| Delivery System Engineering Solutions | 0 | 2 | 0 | 0 | Tran presents a technical breakdown of delivery vector engineering including AAVs, LNPs, and electroporation. As a solo presentation, host scores are strictly zero. | |
| Protein Engineering and Advanced Molecular Tools | 0 | 2 | 0 | 0 | Tran details protein engineering solutions for off-target effects and synthetic biology switches. The host does not interject or participate. | |
| Computational AI and Metagenomic Mining | 0 | 2 | 0 | 0 | Tran explores computational guide RNA design, off-target prediction heatmaps, and metagenomic mining in extreme environments. No host presence is detected. | |
| Ecosystem Dynamics and Entrepreneurial Opportunities | 0 | 2 | 0 | 0 | Tran discusses manufacturing bottlenecks and outlines key criteria A16Z Bio looks for in biotech founding teams. The episode concludes as a full monologue without host dialogue. |
Statements from this episode (19)
Tran: Gene editing is becoming a top therapeutic tool in history
“Technology is used to rewrite our genetic code is becoming one of the most powerful therapeutic arsenals of all time.”
Andy Tran: Gene Editing Enables Curative Single-Dose Treatments
“Of course, this is certainly a big paradigm shift and very exciting as these technologies have given us the power to precisely target And eliminate the origin of disease, as well as be very curative with just a single dose of the drug.”
Tran: 24 gene therapies slated for Phase 3 trials in 2019
“There are about two dozen more gene therapies that are slated to just have phase three trials in this year alone.”
Tran predicts 10 to 20 gene therapy approvals annually by 2030
“We're expecting at least 10 to 20 gene therapy approvals per year by the end of the decade.”
Andy Tran: Gene therapy startups drove major biotech exits
“In fact, taking a look at the past several years, some of the largest biotech exits have been from companies developing these gene therapies.”
Tran: CRISPR cut gene editing engineering timelines from months to days
“Compared to old tools, engineering was cut down from a few months to a matter of weeks or days.”
Tran: Alternative Cas nucleases offer advantages in size and precision over Cas9
“Some Cas nucleases are much smaller, come from less immunogenic strains, are more precise, or have new mechanisms altogether.”
Tran: CRISPR is evolving into a cellular search engine platform
“Instead of just this pair of molecular scissors that everyone talks about, the biggest recent shift in the field is this push towards making CRISPR a search engine platform of the cell.”
Tran: Single-base genome editing enables treatment of previously untreatable SNP diseases
“This limit of precision actually opens the door for addressing an entire field of devastating SNP-based genetic diseases that were previously untreatable before.”
Tran: CRISPR tools can directly target and edit RNA bases
“We can even now directly target and edit RNA bases, opening up the entire field of transcriptomic editing.”
Tran: FDA and CBER introduced accelerated approval guidance for gene therapies
“This past year we've seen FDA and CBER leaders drum up plans to make a big push on assessing new cell and gene therapies, as well as introducing new guidance on accelerated approvals for these new areas of product development.”
Andy Tran: AAVs are the only clinically approved gene therapy vectors
“To jump in, probably the natural place to start is on the AV side, as these adeno-associated viruses are the only clinically approved vector so far for gene therapy.”
Andy Tran: Gene therapy winners will pair platforms with disease-specific optimization
“Regardless of the type of vector that you're engineering, we believe the winners in the space are the ones that could harness a specific platform and marry it with very thoughtful optimization towards specific disease areas.”
Tran: Current genome editing tools face immunogenicity and off-target issues
“Once it is inside the cell, many of our current protein-based genome editing nucleases are still plagued by off-target effects, low efficiency, and side effects from the immunogenicity of the protein itself.”
Tran: Metagenomic mining will uncover genome editing systems beyond CRISPR
“As we continue to mine new metagenomic data of new species, it's not crazy to think that perhaps even CRISPR itself is by no means the final frontier of genome engineering.”
Tran: Manufacturing is an overlooked existential threat to gene therapy
“So once you've designed the perfect gene therapy, perhaps one of the most overlooked, but most existential threats to the industry is challenges in manufacturing.”
Tran: Big biotech giants seek acquisitions in viral vector processing
“A lot of these big biotech product development giants are looking to acquire, you know, smaller companies that have deep expertise in viral vector processing.”
Tran: Simple CRISPR knockouts often outperform complex new genome engineering tools
“Many times, the latest, most advanced, mechanistically complex, and by definition least validated system is not the best tool if a simple CRISPR knockout, for instance, can solve your problem.”
Tran: Genome Engineering Will Eventually Treat Common Chronic Diseases
“As the technology, infrastructure, and economics of these drugs continue to progress, it is not too far-fetched to think of a future in which eventually many of our most devastating diseases, even more common chronic ones, can be targeted and treatable with th…”